Case Report: Enfortumab vedotin and pembrolizumab in androgen pathway modulation-naive prostate cancer with high-volume metastatic burden
Year: 2026
Type: article
Study design: Case Report
Abstract: In recent history, enfortumab vedotin (EV) in combination with pembrolizumab (EV-pembrolizumab) has emerged at the front line of treatment in urothelial carcinoma for its marked efficacy and tolerability measured against prior standard-of-care chemotherapies. Advanced prostate cancer remains a universally incurable disease. We present, for the first time in the literature, a case of marked objective and clinical response to EV-pembrolizumab in androgen pathway modulator-naive prostate cancer with high-volume metastatic burden, offering unique insight and consideration for a new therapeutic approach in a challenging and common advanced disease.
Source: Frontiers in Oncology
Institutions: Duke University, Duke Medical Center
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7234489018
